Recent Updates on Management of Diffuse Large B-Cell Lymphoma

Greg Nowakowski, MD, discusses considerations in treating a newly diagnosed patient with DLBCL.

Loretta Nastoupil, MD, provides insight on treatment considerations after receiving molecular testing results in patients with newly diagnosed DLBCL.

A panel of experts explain how they approach CNS prophylaxis in DLBCL.

David Rizzieri, MD, discusses new data from the ASCO 2021 Virtual Meeting regarding CNS lymphoma and treatment approaches in this setting.

Cyrus Khan, MD, reviews the management of DLBCL after relapse on frontline therapy.

Key opinion leaders discuss recommended second-line treatment options for patients with DLBCL.

Greg Nowakowski, MD [Mayo Clinic, Rochester, Minnesota], reviews the data from the L-MIND trial of tafasitamab and lenalidomide for transplant-ineligible patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma).

Key opinion leaders highlight treatment approaches for patients with DLBCL (diffuse large B-cell lymphoma) who are ineligible for transplant.

A panel of experts review the FDA approvals of loncastuximab tesirine and selinexor for the treatment of DLBCL in patients who have received at least 2 prior therapies.

Experts in lymphoma explain when and for which patients CAR T therapies are recommended in R/R DLBCL.

A panel of experts explain the differences among the multiple trial designs, patient populations, and CAR T constructs used for treatment of non-Hodgkin lymphoma.

Greg Nowakowski, MD, explains optimal approaches to bridging therapy before CAR T cell therapy in DLBCL.

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

Key opinion leaders in lymphoma take a look at challenges in treating B-cell lymphoma and where they see the things moving in the future.

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.